A 2023 study published in the New England Journal of Medicine found that semaglutide produced clinically meaningful weight loss in over 90% of participants, outperforming naltrexone-bupropion combinations by a significant margin
doi: 10.3389/fphar.2018.01168 Summary Keywords Type A insulin resistance syndrome, glucagon-like peptide-1 receptor agonist, sodium-glucose cotransporter 2 inhibitor, diabetes, insulin resistance Citation Martnez-Montoro JI, Pinzn-Martn JL, Damas-Fuentes M, Fernndez-Valero A and Tinahones FJ (2022) Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
10.1111/j.1749-6632.1998.tb09546.x 68
As every patient responds differently, ongoing clinical review and an individualised approach remain essential throughout treatment
Work with your provider's office to gather the necessary information for an appeal, which might include more detailed medical records or a letter from your doctor
